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ABSTRACT
ASDs (autism spectrum disorders) are a complex group of
neurodevelopment disorders,still poorlyunderstood,steadily
rising in frequency and treatment refractory. Extensive
research has been so far unable to explain the aetiology of
this condition, whereas a growing body of evidence suggests
the involvement of environmental factors. Phthalates, given
their extensive use and their persistence, are ubiquitous
environmental contaminants. They are EDs (endocrine
disruptors) suspected to interfere with neurodevelopment.
Therefore they represent interesting candidate risk factors
for ASD pathogenesis. The aim of this study was to evaluate
the levels of the primary and secondary metabolites of DEHP
[di-(2-ethylhexyl) phthalate] in children with ASD. A total of
48 children with ASD (male: 36, female: 12; mean age:
11¡5 years) and age- and sex-comparable 45 HCs (healthy
controls; male: 25, female: 20; mean age: 12¡5 years) were
enrolled. A diagnostic methodology, based on the deter-
mination of urinary concentrations of DEHP metabolites by
HPLC-ESI-MS (HPLC electrospray ionization MS), was applied
to urine spot samples. MEHP [mono-(2-ethylhexenyl) 1,2-
benzenedicarboxylate], 6-OH-MEHP [mono-(2-ethyl-6-
hydroxyhexyl) 1,2-benzenedicarboxylate], 5-OH-MEHP
[mono-(2-ethyl-5-hydroxyhexyl) 1,2-benzenedicarboxylate]
and 5-oxo-MEHP [mono-(2-ethyl-5-oxohexyl) 1,2-benzene-
dicarboxylate] were measured and compared with unequi-
vocally characterized, pure synthetic compounds (.98%)
taken as standard. In ASD patients, significant increase in 5-
OH-MEHP (52.1%, median 0.18) and 5-oxo-MEHP (46.0%,
median 0.096) urinary concentrations were detected, with a
significant positive correlation between 5-OH-MEHP and 5-
oxo-MEHP (rs50.668, P,0.0001). The fully oxidized form
5-oxo-MEHP showed 91.1% specificity in identifying patients
with ASDs. Our findings demonstrate for the first time an
association between phthalates exposure and ASDs, thus
suggesting a previously unrecognized role for these ubiquit-
ous environmental contaminants in the pathogenesis of
autism.
Key words: autism, di-(2-ethylhexyl) phthalate, endocrine
disrupters, HPLC-ESI-MS urine analysis, secondary meta-
bolites.
INTRODUCTION
ASDs (autism spectrum disorders), also known as PDDs
(pervasive developmental disorders), are a group of complex
neurodevelopment disorders, characterized by social impair-
ments, communication difficulties, and restricted, repetitive
and stereotyped patterns of behaviour.
A dramatic increase in frequency of ASDs has been
reported over the last 20 years (Weintraub, 2011; Kim et al.,
2011). Nevertheless, it is difficult to determine how much of
this increase may be due to actual increase in the incidence or
to increased awareness and diagnosis. The aetiology is
unknown, but it is believed to result from disruption of normal
neurobiological mechanisms primarily in the prenatal period
(Nelson, 1991). Although it is widely recognized that ASDs may
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asnneuro.org / Volume 4 (4) / art:e00089 223have a strong genetic component (Risch et al., 1999; Anney
et al., 2011). To the best of our clinical experience, not more
than 5% of all autism cases appear to be due primarily to single
gene mutations. In particular, syndromic ASD accounts for 15–
20% of ASDs, and other complex genetic factors appear to play
a major roleinnon-syndromic formsof autism.World literature
evidence seems to indicate that autism has a strong genetic
component (10–20%, Geschwind, 2011) which, by itself, does
not fully explain the prevalence of the disorder exponentially
increasing overthe last two decades. It is quite likely that
exposure to potential environmental factors has differential
effects depending on genetic background.
According to our observation, the focus of autism research
is shifting from purely genetic influences to multifactorial
diseases in which complex set of genes should be associated
with relevant environmental factors (Larsson et al., 2009;
Herbert, 2010). To date, no information is available on the
potential role in the pathogenesis of autism for phthalates,
ubiquitous contaminants (Griffiths et al., 1985; Bauer and
Herrmann, 1997) used as plasticizers, solvents and additives in
many consumer products, i.e. vinyl flooring, wall coverings,
food containers and cosmetics (Schettler, 2006; Wormuth
et al., 2006). In particular, DEHP [di-(2-ethylhexyl) phthalate]
represents one of the most commonly used plasticizer in
pharmaceutical and medical devices (U.S. FDA 2011). DEHP is
primarily metabolized to monoester, further oxidized in v
and v-1 positions leading to a pool of secondary metabolites
(Albro, 1986; Koch et al., 2003, 2006), and it can be
hypothesized that all DEHP metabolites, derived from a
hydrolytic/oxidative pathway could, after glucuronidation, be
excreted in urine (Figure 1).
Children are known to be exposed to DEHP levels twice as
high as those for adults (Hellerstedt et al., 2008; Wittassek
et al., 2009). Foetuses and neonates are highly sensitive to
physiologically active agents because they are exposed during
critical periods of human development (Latini et al., 2003; Kim
et al., 2009; Cho et al., 2010; Suzuki et al., 2010). Furthermore,
in the case of intensive therapy procedures, neonates can have
higher exposure to phthalates and to their toxic monoesters
supposed to be EDs (endocrine disruptors) (Silva et al., 2003a,
2003b;Latinietal.,2004).EDsmayalsobetransferredfromthe
mother to the developing foetus across the placenta or to
the newborn through breast-feeding (Hines et al., 2009; Latini
et al., 2009). For these reasons, the French National Assembly
has required the ban of phthalates and parabens (Bill of Law
adopted by French National Assembly on 3 May 2011).
Moreover, very recently, prenatal phthalate exposure has been
reported to decrease child mental/motor development, and
increase internalizing behaviour during the preschool years
(Whyatt et al., 2011), thus consolidating the concept of an
adverse effect of these contaminants on function of the CNS
(central nervous system).
The aim of the present study was to evaluate the levels of
the primary and secondary metabolites of DEHP in autistic
children by using innovative chemical reverse approach
(Alcaro et al., 2009; Papini, 2009).
MATERIALS AND METHODS
Subject population
A total of 48 children with ASD (male: 36, female: 12; age at
examination: 11.0¡5 years) were recruited from the staff of
Children Neuropsychiatric Department, Siena, Italy. All the
48 patients with ASD, diagnosed by DSM IV (Diagnostic and
Statistical Manual of mental disorders) and evaluated using
ADOS (autism diagnostic observation schedule), ABC (autism
behaviour checklist) and CARS (childhood autism rating scale)
scores entered the study. Patients with Rett syndrome, X-
fragile syndrome, inborn errors of metabolism, 21 trisomy,
tuberous sclerosis and gene microdeletions were excluded
from the present study. Informed consent from the parents or
Figure 1 Metabolism of DEHP
(A) Hydrolytic/oxidative pathway leading to MEHP and secondary metabolite
formation. (B) Formation of glucuronic conjugates of DEHP metabolites.
C. Testa and others
224 E 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.tutors was obtained, and institutional review board approval
was obtained for the study. Mean age at diagnosis was
between 30 and 36 months. However, the diagnosis for the
examined ASDs population go back to procedures employed
several years ago (today, mean age at the diagnosis for
infantile autism is about 18–24 months). Forty-five gender-
and age-comparable HCs (healthy controls) [male: 25, female:
20; age at examination: 12¡5 years] were randomly chosen
from outpatients who had no pathological symptoms.
Urine from children with ASD and HCs were collected in
polypropylene specimen cups, divided into aliquots (1.0 ml) and
frozen at 220˚C until analysis. Field blanks consisted in purified
water collected in polypropylene tubes and frozen at 220˚C.
Determining secondary metabolites in urine
The metabolites measured in this study included: MEHP [mono-
(2-ethylhexenyl) 1,2-benzenedicarboxylate] and 6-OH-MEHP
[mono-(2-ethyl-6-hydroxyhexyl) 1,2-benzenedicarboxylate],
5-oxo-MEHP [mono-(2-ethyl-5-oxohexyl) 1,2-benzenedicar-
boxylate] and 5-OH-MEHP [mono-(2-ethyl-5-hydroxyhexyl)
1,2-benzenedicarboxylate]. All these metabolites were synthe-
sized in the Laboratory of Peptide and Protein Chemistry and
Biology (PeptLab) following their previously described proced-
ure (Nuti et al., 2005). The unequivocally characterized
synthetic metabolites were used as pure analytical standards
(.98% purity) for quantitative determination in urine from
ASD children and HCs.
All the solvents (acetonitrile, water, buffers, etc.), labware
(polypropylene vials containing urine, solvent bottles, SPE
(solid phase extraction) cartridge, Teflon capped-glass bottles,
pipettes) and instrumentation used during SPE procedure and
the HPLC-ESI-MS (HPLC electrospray ionization MS) analyt-
ical process, to detect MEHP and/or secondary metabolites
in ASD patients and HCs, were verified to be MEHP– and
secondary oxidative metabolites-free. The internal standards
were prepared in acetonitrile and were used as reported in
the literature (Blount et al., 2000; Kato et al., 2004).
First morning urine specimens were collected. All speci-
mens displayed urinary creatinine in the children reference
value range, dependent on age and lean body mass (0.5–
4.0mg/kg per 24 h). For creatinine measurement, we used a
Synchron AS/ASTRA clinical analyser (Beckman Instruments).
We used values (mg/l) for creatinine and (g/l) for dilution
correction in the analyses.
For SPE treatment of urine, we prepared the following
buffers: ammonium acetate buffer1 M, pH 6.5;acidbuffer,pH
2.0 by preparing a solution of NaH2PO4 (0.14 M) and 1% of
85% H3PO4; basic buffer was prepared by adding concentrated
ammonium hydroxide (1 ml of 30% NH3 solution) to a 50:50
acetonitrile/water (200 ml). All buffers were stored in sealed
bottles at room temperature (20˚C): basic buffer was discarded
after 1 week, acid buffer after 1 month.
Human urines (1 ml) were defrosted, sonicated, mixed and
dispensed in glass tubes. Then ammonium acetate buffer (250
ml, pH 6.5) was added. Incubation with b-glucoronidase (5 ml,
200 units/ml, Roche Biochemical) was performed at 37˚C for
90 min, resulting in quantitative glucuronide hydrolysis of
phthalates and metabolites. Escherichia coli K12 b-glucur-
onidase has excellent glucuronidase activity and no mea-
surable lipase activity on phthalate diesters (Blount et al.,
2000; Kato et al., 2004). After deconjugation, samples were
treated with two steps of SPE, using SPE cartridge (3 ml/
60 mg of Oasis HBL, Waters) to remove any contamination of
biological matrix, following the procedure described by
Blount et al. (2000). The first cartridge was used to retain
hydrophobic compounds while the phthalate metabolites
were eluted. The second cartridge was helpful in removing
residual salts. Analytes were finally eluted with acetonitrile
and ethyl acetate, concentrated, re-suspended in water and
transferred into vials. All the samples were analysed by RP-
HPLC-ESI-MS (reverse-phase HPLC-ESI-MS). One blank and
one QC (quality control) sample were included in each batch
of samples. The QC sample was spiked with pooled urine and
MEHP and secondary oxidative metabolite standards in
known concentration (200 ng/ml). When urine analysis
resulted in values for metabolite concentrations exceeding
the linear range of the analytical method, we subjected a new
aliquot of the same sample to the entire process (deconjuga-
tion and SPE) and we analysed again. Before analysis, known
concentration samples were treated by SPE and analysed by
RP-HPLC-ESI-MS to test SPE efficiency. In our study the
efficiency of SPE procedure is in accordance with the
literature (Mazzeo et al., 2007). Treated urine samples could
be stored at 4˚C without degradation. Storage of untreated
urines at 240˚C for 6 months showed no decrease in
phthalate monoester levels.
The analytical methodology adapted for measuring MEHP
and secondary oxidative metabolites in urine had already
been described in the literature (Blount et al., 2000; Silva
et al., 2003a, 2003b; Kato et al., 2005).
In particular, we used an HPLC tandem MS, RP-HPLC-ESI-
MS (Waters, Alliance 2695, Waters, Micromass ZQ) equipped
with phenyl column (Betasil, 5 mm, 50 mm63 mm, Keystone
Scientific) and with a Waters 2996 Photodiode Array
Detector. All reagents were of at least analytical reagent
grade. The lower LOQs (limits of quantification) were 0.042
mg/l MEHP, 0.048 mg/l 5-OH-MEHP, 0.049 mg/l 5-oxo-MEHP
and 0.008 mg/l 6-OH-MEHP. In urine, the LODs (limits of
detection) were 0.014 mg/l MEHP, 0.016 mg/l 5-OH-MEHP,
0.016 mg/l 5-oxo-MEHP and 0.002 mg/l 6-OH-MEHP. The
chromatographic separations of metabolites were resolved
using a linear gradient from 3 to 60% B in 10 min (solvent
system A: 0.1% acetic acid in water; B: 0.1% acetic acid in
acetonitrile). The flow rate was 0.6 ml/min. The column
temperature was 32˚C. A guard column (XBridgeTm Phenyl
3.5 mm, 3.0620 mm) was used to prevent column degrada-
tion. Column eluates were monitored at 215, 230 and
254 nm. The mass-specific detection was achieved using a
Waters, Micromass ZQ ESI in positive ion mode. The product
ion with higher signal intensity was selected for the
quantitative analysis for each of the four phthalates. The
Secondary metabolite detection in autism
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225optimal MS parameters were as follows: the source and
desolvation temperature were 120 and 400˚C respectively;
the capillary voltage was 3.24 kV; cone voltage 30 kV,
nitrogen gas was used as desolvatation gas and as cone gas
as well; the cone gas and the desolvatation flow was 60 and
800 l/h respectively; the collision gas was argon with a flow
of 0.60 ml/min. Data were acquired and processed using
MassLynx
TM software (Waters).
Calibration curves for the quantitative urine analysis were
calculated for all analytes plotting peak area average (y)
against concentration of standards (x). Five standard solu-
tions (linear range: 2.5–2500 ng/ml) for calibration curve
plotting, were prepared for all the metabolites. Curves with
correlation coefficients (r
2) greater than 0.998 were gener-
ated (MEHP, 5-OH-MEHP, 5-oxo-MEHP 0.999 and 6-OH-
MEHP 0.998).
Statistical analysis
All variables were tested for normal distribution (D’Agostino-
Pearson test) and data were presented as means with 95% CI
(confidence interval) for normally distributed variables or medians
means and with 95% CI for non-normally distributed data.
Differences between groups were evaluated using independent-
sample t test (continuous normally distributed data), Mann–
Whitney rank sum test (continuous non-normally distributed
data), x2 statistics(categoricalvariableswithminimumnumber of
cases per cell >5) of Fisher’s exact test (categorical variables with
minimum number of cases per cell ,5). Associations between
variables were tested by unvaried regression analysis. The
efficiency of urinary phthalates metabolites in discriminating
ASD patients from HCs were evaluated using ROC (receiver
operating characteristic) curve analyses. All analyses were
considered to be statistically significant for P-values ,0.05. Cor-
rection for multiple comparisons was made (Bonferroni’s
correction). The MedCalc version 9.5.2.0 statistical software
package (MedCalc Software) was used.
RESULTS
Among the four metabolites (MEHP and secondary oxidative
metabolites) measured in urines of ASDs, we could detect
urinary concentration with median values for MEHP (0.055
mg/ml), 5-OH-MEHP (0.18 mg/ml), 6-OH-MEHP (0.017 mg/ml)
and 5-oxo-MEHP (0.096 mg/ml). By contrast, in urine from
HCs we found the following values for MEHP (0.028 mg/ml),
5-OH-MEHP (0.04 mg/ml), 6-OH-MEHP (0.019 mg/ml) and 5-
oxo-MEHP (0.04 mg/ml). However, the data illustrated in
Table 2 are without urinary creatinine correction. Differences
between groups by using creatinine-adjusted data were
comparable with those employing raw data (data not shown).
The statistical significance of variables was independent of
effects of urinary creatinine concentration. In fact, it is well
known that urine concentration/dilution can affect the
results of measurements of urinary metabolites.
We found detectable levels of MEHP, 5-OH-MEHP and 5-
oxo-MEHP in 79.2, 52.1 and 46.0% of ASD patients
respectively (Table 1). Interestingly, 5-OH-MEHP was the
major metabolite in terms of urine concentrations, followed
by 5-oxo-MEHP and MEHP. Urinary excretion of 5-oxo-MEHP
(P50.005), 5-OH-MEHP (P50.0224) and MEHP (P50.0312)
was significantly higher in autistic patients compared with
gender- and age-comparable HCs (Table 2). By contrast,
6-OH-MEHP (P50.9305) was not able to discriminate ASDs.
High levels of 5-OH-MEHP were detected in 26.6% of HCs. A
significant positive correlation between 5-OH-MEHP and 5-
oxo-MEHP could be observed only in autistic children
(rs50.668, P,0.0001), but not in the control population
(rs50.125, P50.5565) (data not shown). The completely
oxidized form of the metabolite pathway, corresponding to
5-oxo-MEHP, had a specificity of 91.1% in identifying
autistic children (Figure 2).
The efficiency of urinary secondary metabolites in
discriminating ASD patients from HCs was evaluated using
ROC curve analyses (Figure 3, Tables 1 and 2).
Table 1 ROC for DHEP secondary metabolite urinary excretion and infantile autism
AUC, area under curve; 95% CI, 95% confidence intervals for the AUC; Sens., sensitivity; spec., specificity; +PV, positive value; 2PV, negative value;
ALL, total sum of all the examined di(2-ethylhexyl)phthalate secondary metabolites (5-OH-MEHP+5-oxo-MEHP+6-OH-MEHP+MEHP).
Urinary phthalate Cut-off AUC¡S.E.M. 95% CI P-value Sens (%) Spec. (%) +PV (%) 2PV (%)
5-OH-MEHP .0.177 0.638¡0.057 0.531–0.735 0.0154 52.1 75.6 69.4 59.6
5-Oxo-MEHP .0.142 0.666¡0.055 0.561–0.759 0.0028 46.0 91.1 85.2 60.3
MEHP .0.01 0.631¡0.058 0.524–0.730 0.0233 79.2 44.2 61.3 65.5
ALL .0.724 0.671¡0.055 0.568–0.764 0.0021 39.2 97.8 95.2 58.7
Table 2 Comparisons of urinary excretion of secondary metabolites for DEHP in autistic patients (n548) versus HCs (n545) in mg/ml
Values are medians (95% confidence intervals of the median).
ASD healthy Controls P-value*
5-OH-MEHP 0.18 (0.037–0.399) 0.04 (0–0.124) 0.0224
5-Oxo-MEHP 0.096 (0.04–0.17) 0.04 (0.015–0.079) 0.005
6-OH-MEHP 0.017 (0.01–0.034) 0.019 (0–0.043) 0.9305
MEHP 0.055 (0–0.11) 0.028 (0–0.059) 0.0312
* Mann–Whitney test for independent samples; statistically significant differences are highlighted in bold.
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(childhood autism rating scale) score and levels of the
different metabolites. Total CARS scores were (means¡S.D.)
44¡7.4 (range: 31–60). A positive correlation between CARS
scores and urinary MEHP levels was observed (r50.429,
P50.0033), whereas no significant relationships with the
levels of the other examined metabolites were found (total
CARS versus 5-OH-MEHP: r50.120, P50.4298; total CARS ver-
sus 5-oxo-MEHP: r50.127, P50.3931; total CARS versus
6-OH-MEHP: r50.0085, P50.9529).
Moreover, we compared ASDs with n510 patients with Rett
syndrome(ageneticformofautismdueinupto95%ofcasesto
mutation of a gene, i.e. MeCP2), urinary phthalate metabolites
appear to be, once again, significantly elevated in ASD patients
(Table 3). Actual behaviour for most patients with Rett
syndrome is not autistic even if all of them do show autistic
traits during stage 2 of the disease. Therefore 5-oxo-MEHP urin-
ary excretion appears to be lower in Rett syndrome (P50.0344),
whereas 5-OH-MEHP (P50.0601), 6-OH-MEHP (P50.2246) and
MEHP(P50.7098) excretion is comparable withthat observedin
HCs, despite the heavy medication needed in this multi-system
genetic disease. These resultsindicate that medications are likely
notthemaincausefortheincreasedurinaryphthalateexcretion
evidenced in ASDs, while suggesting the likely intervention of
environmental factors in the pathogenesis of this pervasive
development disorder.
DISCUSSION
As ASDs are disorders of brain development, any factors that
regulate brain development and are known to be altered in autism
should be considered as possibly contributing to the phenotype.
Our findings, for the first time, demonstrate an association
between phthalates and ASDs. It is interesting to note that, in
87% of the ASD urine samples, we detected MEHP and
5-oxo-MEHP levels higher than the levels recently reported,
by Cho et al. (2010). In that study Cho et al. reported a
possible relationship between environmental phthalate expo-
sure (external contamination) and the intelligence level of
667 school-age children randomly recruited from nine
elementary schools in five South Korean cities. The reported
median values were for MEHP (0.055 mg/ml), 5-OH-MEHP
(0.18 mg/ml) and 5-oxo-MEHP (0.096 mg/ml) respectively. As
spot urines are among the most commonly used samples in
clinical toxicology, we showed the data unadjusted for
creatinine. In fact, in epidemiological studies it is not
practical to collect 24 h urine samples or, when young
children are involved, even first morning voids. In particular,
spot urines have also been used in a widely promoted paper
relating maternal urinary-phthalate metabolite excretion in
mothers to psychomotor development in their children at age
3, recently published (Whyatt et al., 2011). Likewise in ASDs,
MEHP was found to be the minor urinary metabolite
compared with the corresponding oxidized metabolites as in
some adult metabolic diseases (Wittassek and Angerer, 2008).
It is possible to hypothesize that, in the case of ASDs, a high
MEHP urinary excretion does not correspond to external
contamination, but rather MEHP could likely act as an ED.
From our data it is possible to speculate that phthalate
metabolites as EDs may play an important and previously not
recognized role eitherin the neurotransmitter systemand/orin
neurodevelopment, possibly increasing the risk of ASDs. In any
case, our findings indicate for the first time that specific DEHP
metabolites are statistically significantly increased in ASDs. It is
intriguing that urinary levels of the most oxidized form of the
DEHP metabolites (5-oxo-MEHP) is able to efficiently discrim-
inate ASDs from HCs (Figure 2). Nevertheless, it has already
Figure 2 Differences between groups: scatterplots for 5-oxo-MEHP
values in ASDs urine samples (ASDs, n548; HC, n545)
Data are medians and inter-quartile range.
Figure 3 ROC curve analysis (ASD patients versus HC) for DEHP
metabolites
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227been reported that the most oxidized DEHP metabolites have
longer half-life of excretion in urine (Koch et al., 2006).
Therefore it is possible that environmental factors and OS
(oxidative stress) imbalance may interact in leading to
increased ASD risk, although further investigation is needed
in dissecting this interaction in vivo.
A link between oxidative brain damage and ASD has been
previously reported by several authors (James et al., 2004;
Villagonzalo et al., 2010; Sajdel-Sulkowska et al., 2011). Over
the last few years, our team has demonstrated that the
biological ’duo’ hypoxia–OS is a key player in modulating
genotype–phenotype expression in Rett syndrome, a well-
established genetic form of ASD (De Felice et al., 2009;
Pecorelli et al., 2011; Signorini et al., 2011).
Moreover, in previous reports, a correlation between OS
and ASD has been widely explored by measuring different
molecules, possibly coming from oxidative pathway as
metabolic biomarkers of OS, in biological fluids (Chauhan
et al., 2004; James et al., 2004).
Tothebestofourknowledge,astrictrelationshipbetweenOS
entity and the in vivo presence of oxidized forms of DEHP has
not been reported before. Therefore we could speculate that, in
susceptible subjects, DEHP exposure, when finding OS condi-
tions, can lead to in vivo accumulation of toxic metabolites (i.e.
the oxidized phthalate metabolites), possibly acting as EDs.
Considering that urinary 5-oxo-MEHP reported in our study as
i n c r e a s e di nA S D sc o m p a r e dw i t hH C s ,w ec a ns t a t et h a to u r
findings are in agreement with an increased OS environment.
Moreover, phthalates are known as EDs, but it is unclear
how they could be involved in aetiology of neurodevelop-
ment disorders. Phthalate metabolites activate a-PPARa
(peroxisome proliferator-activated receptor a), interfering
with cellular proliferation and lipid metabolism. Activation of
PPARa by phthalates may alter lipid metabolism in the brain
(Clark-Taylor and Clark-Taylor, 2004). Recently the signal
transduction pathway of PPARa was correlated with
progression of neurodegenerative and psychiatric diseases.
Phthalates also interfere with the TH (thyroid hormone)
system by inducing hypothyroidism. Recent studies correlated
in utero hypothyroxinaemia to decreased intellectual capa-
city, mental retardation and ASD (Roman, 2007), thus
reinforcing our speculation. Moreover, exposure to DBP (di-
n-butyl phthalate) seems to affect thyroid activity in
pregnant women, thus leading to adverse effects on the
foetus (Huang et al., 2007).
On the other hand, transient intra-uterine deficits of THs
have been shown to result in permanent alterations of
cerebral cortex similar to those found in brains of children
with autism (Roman, 2007). As a consequence, the current
surge of this disease could be related to transient maternal
hypothyroxinemia resulting from exposure to anti-thyroid
environmental contaminants.
For the first time in this study we correlated different
levels of the primary and secondary metabolites with ASDs
compared with HC children. These data generate the idea that
either current exposure is higher in children with ASD, or
alternatively, and more likely, ASD children may differ in their
ability to metabolize phthalates.
In conclusion, our findings generate the idea that prenatal
plus postnatal phthalate exposure may have synergistic and
cumulative actions affecting brain development, thus pos-
sibly contributing to the ASD phenotype, according to the
general concept generated by Herbert (2010) of ’environ-
mentally vulnerable physiology’. Therefore a prenatal/
postnatal screening for urinary DEHP metabolites in the
population at high risk for ASDs could have an important
social impact.
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